Chinese Local Pharmas See Innovative Products As Future Growth Driver - China Healthcare Investment Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Fueled by the Chinese government's latest five-year plan that will promote innovation and increase exports of finished products, Chinese domestic companies are increasing their R&D efforts to ensure future growth, companies said during the second annual China Healthcare Investment conference March 23
You may also be interested in...
Traditional Chinese Medicines Seen As Global Growth Opportunity
HONG KONG - Health authorities around the world are working to develop regulatory structures for traditional Chinese medicines
Traditional Chinese Medicines Seen As Global Growth Opportunity
HONG KONG - Health authorities around the world are working to develop regulatory structures for traditional Chinese medicines
China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market